Dermatology Doctors in Weymouth, MA Accepting Medicare

4 Dermatology doctors found. Showing 1 - 4

Mrs. Teresa Degiacomo, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 90 Libbey Pkwy, Suite 200, Weymouth, MA 02189 Phone: 781-335-9700    Fax: 781-335-9709

Heidi Flora Anderson-dockter, M.D. Dermatology - MOHS-Micrographic Surgery Medicare: Accepting Medicare Assignments Practice Location: 90 Libbey Pkwy, Suite 200, Weymouth, MA 02189 Phone: 781-335-9700    Fax: 781-335-9709

Courtney Reilly Csikesz, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 90 Libbey Pkwy, Suite 200, Weymouth, MA 02189 Phone: 781-335-9700    Fax: 781-335-9709

Mrs. Susan Decoste, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 90 Libbey Pkwy, Suite 200, Weymouth, MA 02189 Phone: 781-335-9700    Fax: 781-335-9709

News Archive

Targeted molecular therapy reduces initial development of NAFLD in mice

Researchers report in the journal Cell Reports a targeted molecular therapy that dramatically reduces the initial development of Non Alcoholic Fatty Liver Disease (NAFLD) in laboratory mouse models of the disease.

Monoclonal antibody effectively blocks development of graft-versus-host disease, research shows

Newly published research provides preclinical proof-of-concept for the ability of PRO 140, a humanized anti-CCR5 monoclonal antibody under development by CytoDyn Inc., to effectively block the development of graft-versus-host disease (GvHD), a potentially lethal complication of bone marrow stem cell (BMSC) transplantation.

New technology makes it easier to diagnose neurodegenerative diseases

A new combination of optical coherence tomography (OCT), adaptive optics and deep neural networks should enable better diagnosis and monitoring for neuron-damaging eye and brain diseases like glaucoma.

Biomoda granted Mexican patent for proprietary porphyrin-based compound

Cancer diagnostics company Biomoda, Inc. has been granted a Mexican patent for its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce red under ultraviolet light.

Cyclacel opens enrollment of sapacitabine Phase 3 trial for AML

Cyclacel Pharmaceuticals, Inc., today announced that it has opened enrollment of the SEAMLESS pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment of elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.

Read more Medical News

› Verified 5 days ago